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Abstract
Encapsidation of human immunodeficiency virus type 1 (HIV-1) RNA involves specific interactions between viral Gag proteins and viral
RNA elements located at the 5 untranslated region (UTR). These RNA elements are termed packaging () or encapsidation (E) signals and
mainly comprise the stem-loop 1 (SL1) and SL3 RNA structures. We have previously shown that deletion of the SL1 sequences is
compensated by second-site mutations within Gag. Similar studies are now extended to SL3 and the results demonstrate that deletion of this
RNA structure is rescued by two point mutations, i.e., A11V in p2 and I12V in nucleocapsid (NC). These two compensatory mutations are
different from those associated with the rescue of SL1 deletion, suggesting that SL1 and SL3 may bind to different residues of Gag during
viral RNA packaging. Analysis of virion-derived RNA in native agarose gels shows that deletion of SL3 leads to decreases in both viral
RNA packaging and dimerization. These defects are corrected by the compensatory mutations A11V and I12V. Yet, defects in viral RNA
dimerization at an early stage that were caused by the SL3 deletion in the context of a viral protease-negative mutation cannot be overcome
by these two suppressor mutations. Therefore, the positive effects of A11V and I12V on dimerization of the SL3-deleted RNA must have
taken place at the maturation stage.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Human immunodeficiency virus type 1 (HIV-1) selec-
tively packages full-length viral RNA as its genome over a
high background of cellular RNA in the cytoplasm. This
process involves specific binding of HIV-1 Gag proteins to
cis-acting viral RNA elements, termed  or encapsidation
(E) signals. Early mutagenesis studies have mapped the E
signals to a region located between the 5 major splice
donor (SD) site and the 5 portion of the gag gene; this
region was subsequently shown to contain two RNA stem-
loop (SL) structures, termed SL3 and SL4 (Aldovini and
Young, 1990; Clavel and Orenstein, 1990; Clever et al.,
1995; Hayashi et al., 1992; Lever et al., 1989; Luban and
Goff, 1994). Further studies revealed that RNA sequences
located upstream of the 5 SD site also affected RNA
packaging (Kim et al., 1994); these include the TAR struc-
ture, the poly(A) hairpin, the U5-PBS RNA complex, and
SL1 (Clever et al., 2002; Das et al., 1997, 1998; Harrich et
al., 2000; Liang et al., 2000; McBride and Panganiban,
1997; McBride et al., 1996, 1997).
The nucleocapsid (NC) sequences of Gag protein func-
tion in trans to recognize the E signals and thereby direct
RNA packaging (Aldovini and Young, 1990; Berkowitz and
Goff et al., 1994, 1995; Dorfman et al., 1993; Poon et al.,
1996). Of the multiple RNA structures within the 5 non-
coding RNA leader region, SL1, SL3, and SL4 bind to NC
with high affinity, as shown by in vitro binding assays
(Clever et al., 1995; Berkowitz and Goff, 1994; Berkowitz
et al., 1993, Sakaguchi et al., 1993). In contrast, the TAR,
U5-PBS, and poly(A) elements display low affinity for NC
* Corresponding author. McGill AIDS Centre Rm 326, Lady Davis
Institute-Jewish General Hospital, 3755 Cote Ste-Catherine Road, Mon-
treal, Quebec H3T 1E2, Canada. Fax: 514-340-7537.
E-mail address: chen.liang@mcgill.ca (C. Liang).
R
Available online at www.sciencedirect.com
Virology 314 (2003) 221–228 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0042-6822(03)00405-7
and thus may indirectly participate in RNA packaging by
regulating viral RNA metabolism or by helping to correctly
present the SL1, SL3, and SL4 structures to NC (Clever et
al., 1995).
Aside from its role in viral RNA packaging, SL1 has also
been defined as the dimerization initiation site (DIS). This
function of SL1 is attributable to the palindrome feature of
its loop sequence, which can trigger dimer formation
through “Watson-Crick” basepairing (Clever et al., 1996;
Laughrea and Jette, 1994, 1996; Marquet et al., 1994; Mu-
jeeb et al., 1998; Muriaux et al., 1995, 1996b; Paillart et al.,
1994, 1996; Skripkin et al., 1994). The importance of SL1
in RNA dimerization is also supported by experiments using
mutated viral RNA derived from virus particles (Berkhout
and van Wamel, 1996; Clever and Parslow, 1997; Haddrick
et al., 1996; Laughrea et al., 1997; Shen et al., 2000). We
have previously deleted the SL1 sequences in the context of
full-length viral RNA genome and observed severe defects
in both viral RNA packaging and dimerization (Shen et al.,
2000). Long-term culture of the mutated viruses in permis-
sive cells led to isolation of compensatory mutations within
Gag protein that restored viral infectivity to near wild-type
levels (Liang et al., 1998). Further analysis indicated that
these compensatory mutations corrected the deficient viral
RNA packaging but not RNA dimerization (Shen et al.,
2000). It is thus proposed that viral RNA can be packaged
at high efficiency in the monomeric form.
SL3 represents another major RNA packaging signal
(Berkowitz et al., 1996). We have recently shown that
disruption of the SL3 structure affected both RNA packag-
ing and dimerization (Russell et al., 2003). To further un-
derstand the mechanisms underlying the regulatory roles of
SL1 and SL3 in HIV-1 RNA packaging and dimerization,
we have conducted a compensation study to determine the
second-site mutations that can rescue the deleted SL3 se-
quences. The results show that the suppressor mutations for
the SL3 deletion are different from those for the SL1 dele-
tion, indicating that SL1 and SL3 may bind to Gag proteins
in different ways during encapsidation of viral RNA.
Results
Long-term culture of the (306–325) mutated viruses in
MT-2 cells leads to the appearance of suppressor
mutations in the gag coding region
HIV-1 RNA sequences at nucleotide (nt) 306 to 325
were deleted to remove the SL3 structure; the construct thus
generated was termed (306–325) (Fig. 1A). On the basis
of the structure prediction by the M-fold program (Mathews
et al., 1999; Zuker et al., 1999), this deletion does not
disrupt the flanking RNA secondary structures including
SL1 and SL2 (Fig. 1B). Following transfection of COS-7
cells, the mutated DNA construct (306–325) generated
wild-type levels of full-length as well as spliced viral RNA
as shown by the results of Northern blots (Fig. 1C). This
indicates that the SL2 RNA structure, which contains the
splice donor signal, is not affected by the (306–325)
deletion and thus allows normal splicing of viral RNA. In
support of these results of viral RNA analysis, wild-type
levels of both intracellular Gag proteins and extracellular
Fig. 1. (A) Schematic illustration of the (306–325) deletion. Deleted
sequences are indicated by dash lines. RNA secondary structures are shown
for SL3. LTR, long terminal repeat; SD, splice donor. Numbering of
nucleotides refers to the first nucleotide (nt) in the R region. (B) Effects of
the (306–325) deletion on viral RNA secondary structures. Both the
wild-type BH10 and the (306–325) mutated HIV-1 RNA sequences,
spanning nucleotide positions 243 to 361, were subjected to secondary
structure analysis through use of the M-fold program (Mathews et al.,
1999; Zuker et al., 1999). Locations of the SL1, SL2, and SL3 structures
are indicated. (C) Expression of viral RNA within transfected COS-7 cells.
Total RNA was prepared from COS-7 cells that had been transfected with
either the BH10 or (306–325) DNA constructs, followed by separation on
agarose gels. Northern blotting was performed to detect viral RNA through
use of HIV-1 specific probes. The full-length (9.2 kb) as well as spliced (4
and 2 kb) forms of viral RNA are indicated on the right side of the gels. (D)
Expression of viral proteins and production of virus particles. Transfected
COS-7 cells were subjected to metabolic labeling through use of 35S-
methionine and 35S-cysteine. The intracellular Gag protein and its deriva-
tives were detected by immunoprecipitation using anti-HIV-1 p24 antibod-
ies. 35S-labeled virus particles in the culture fluids were directly assessed
on Sodium dodecyl sulfate–12% polyacrylamide gels and visualized by
exposure to x-ray films. Positions of the protein markers (kDa) are indi-
cated on the right side of the gels.
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virus particles were detected after transfection of this mu-
tated DNA construct into COS-7 cells (Fig. 1D).
The infectivity of the virus particles that were generated
either by the wild-type BH10 or the mutated (306–325)
DNA constructs was then studied through infection of MT-2
cells. The results show that growth of the (306–325)
mutant viruses was significantly delayed in comparison to
the wild-type virus (Fig. 2A). The mutated viruses were
further cultured in MT-2 cells over multiple passages until
wild-type replication phenotypes were observed. Sequenc-
ing of proviral DNA at this stage indicated the retention of
the original SL3 deletion and the emergence of novel sec-
ond-site mutations in the gag coding region, i.e., an A11V
amino acid substitution in p2 and an I12V amino acid
substitution in NC (Fig. 2B). In addition, insertions of a
number of As were seen between nt positions 305 and 306
in the noncoding RNA leader region. Site-directed mu-
tagenesis experiments were then performed to insert these
second-site mutations into the (306–325) construct to de-
termine whether these new mutations were sufficient and
necessary to restore the infectivity of (306–325) to wild-
type levels. The results of infection assays showed that the
A11V mutation in p2 markedly increased the infectiousness
of (306–325); the I12V mutation alone barely augmented
viral replication, but could synergistically increase viral
growth together with A11V (Fig. 2A). The addition of A
residues did not increase the infectivity of (306–325),
either alone or together with A11V and I12V (data are
shown only in regard to the addition of 12 As) (Fig. 2A).
Therefore, second-site mutations in both p2 and NC appar-
ently played key roles in rescue of the defective replication
of (306–325).
The A11V mutation in p2 and the I12V mutation in NC
increase levels of RNA packaging and dimerization
in the (306–325) mutated viruses
SL3 is known to direct specific packaging of HIV-1
genomic RNA. Thus, we hypothesize that the A11V and
I12V mutations must have overcome deficits in packaging
caused by the (306–325) deletion. To test this hypothesis,
viral RNA was prepared from virus particles through pro-
tease K digestion and phenol:chlorophorm extraction in the
presence of 100 mM NaCl, fractionated on native agarose
gels, and analyzed by Northern blotting. The results showed
that the (306–325) deletion led to severe reductions not
only in the levels of total viral RNA but also in the relative
levels of dimeric RNA (Fig. 3, lane 1). Following combi-
nation with the (306–325) deletion, A11V gave rise to a
measurable increase of viral RNA levels (Fig. 3, lane 2),
while the I12V mutation alone was not effective in this
regard (Fig. 3, lane 3). However, A11V and I12V together
restored viral RNA packaging in (306–325) to wild-type
levels and also significantly increased dimer contents in the
mutant virus particles (Fig. 3, lane 4). Therefore, A11V and
I12V acted synergistically to rescue the deficient RNA
packaging and dimerization in (306–325).
We also examined the effects of additional inserted As
on viral RNA dimerization and packaging in (306–325).
The results of Fig. 3 show that neither 9 nor 12 As, inserted
at nt 305, led to any increase in the total levels of (306–
325) RNA (lanes 5 and 6). However, insertion of 15 As
restored wild-type RNA packaging; yet, the majority of
viral RNA exhibited a monomeric form (lane 7). Again, the
A11V and I12V mutations were jointly able to overcome
most of the deficits in RNA packaging and dimerization
caused by the (306–325) deletion in the presence of the
inserted 15 As (lane 8).
We next asked whether the corrected RNA dimers in the
(306–325)-A11V-I12V recombinant viruses possessed
wild-type thermostability. To pursue this subject, viral RNA
samples were treated at various temperatures in the presence
of 100 mM NaCl before separation on native agarose gels.
We first examined dimers retained in the (306–325) mu-
tated viruses. The results of Fig. 4 show that these RNA
dimers dissociated over a range of temperatures similar to
those seen with wild-type dimers. When the (306–325)-
A11V-I12V RNA dimers were analyzed, the same dissoci-
ation temperatures were again observed (Fig. 4). Therefore,
the (306–325) dimers that were formed in the presence of
A11V and I12V mutations exhibit wild-type thermostabil-
ity.
Fig. 2. Compensation of the crippled replication of the (306–325) mu-
tated viruses by second-site mutations within the Gag protein. (A) Repli-
cation of mutated and wild-type viruses in MT-2 cells. Virus growth was
monitored by measuring reverse transcriptase (RT) activity of culture fluids
at various times. Mock infection represents exposure of MT-2 cells to
heat-inactivated wild-type viruses. (B) Second-site mutations identified in
the (306–325) mutated viruses after long-term culture in MT-2 cells. The
changed amino acid residues in the p2 and NC domains are underlined. The
arrow indicates the protease cleavage site between p2 and NC.
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The A11V and I12V substitutions do not correct defective
RNA dimerization caused by the (306–325) deletion in
the context of protease-negative viruses
HIV-1 RNA is initially packaged as immature dimers
that are further converted into mature forms upon release of
the NC protein by protease (PR) cleavage of the Gag protein
(Fu et al., 1994). The immature dimers are readily detected
within the protease-negative virions and exhibit a slightly
slower mobility during electrophoresis as well as lower
stability in comparison to the mature dimers that are asso-
ciated with the wild-type mature virus particles. We wished
to determine whether the (306–325) deletion had exerted
adverse impacts on dimerization at the immature dimer
stage. To pursue this subject, the (306–325) deletion was
combined with a point mutation D25A that eliminates the
enzymatic activity of the HIV-1 PR (Morin et al., 1998), and
the construct thus generated was termed (306–325)-PR.
The D25A substitution was also inserted into wild-type
BH10 to generate BH-PR. In the case of BH-PR, a
significant amount of viral RNA was observed as immature
dimers that migrated at a slower rate than did the wild-type
RNA dimers in BH10 (Fig. 5). This indicates that the
immature dimers are in a relatively loose conformation
compared to the mature dimers (Fu et al., 1994). In contrast,
RNA derived from (306–325)-PR virus was present al-
most exclusively in monomeric form (Fig. 5). These find-
ings suggest that the (306–325) RNA is defective in the
formation of immature dimers during virus assembly.
Next, we asked whether the compensatory mutations
A11V and I12V were able to correct this early dimerization
defect. Accordingly, (306–325), A11V, and I12V were
combined with the PR mutation D25A to yield a construct
(306–325)-R-PR. The results showed that levels of RNA
immature dimers in this latter virus were drastically lower
than those associated with BH-PR (Fig. 5). These data,
together with those shown in Fig. 3, lead to the conclusion
that rescue of deficient dimerization by A11V and I12V
must have taken place during viral maturation following PR
cleavage.
Discussion
In the present study we have identified two second-site
mutations within the Gag protein that can rescue the deleted
Fig. 4. Thermostability of RNA dimers prepared from the (306–325),
(306–325)- A11V-112V, and BH10 viruses. Viral RNA samples were
treated at different temperatures (i.e., 40°C, 45°C, 50°C, and 55°C) in a
buffer containing 100 mM NaCl prior to separation on native agarose gels.
Fig. 3. Effects of the A11V and I12V second-site mutations on deficient
RNA packaging and dimerization of (306–325). Viral RNA was prepared
from virus particles by phenol-chloroform extraction. An amount of viral
RNA equivalent to 150 ng of p24 (CA) antigen was loaded onto native
agarose gels for each construct. Following electrophoresis, viral RNA was
transferred onto nylon membranes and further detected by human immu-
nodeficiency virus type 1 (HIV-1) DNA probes. Positions of dimers and
monomers are indicated on the left side of the gels. Intensities of RNA
signals were calculated by using the NIH Image program and the results are
summarized in the graph. The total levels of wild-type RNA in BH10 were
arbitrarily set at 100. The relative proportion of dimers for each construct
was also determined and the results are shown in the graph. The data shown
are from one representative experiment.
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SL3 sequences. Interestingly, the two mutations, i.e., A11V
in p2 and I12V in NC, are distinct from those previously
characterized for the deleted SL1 sequences, which include
substitutions T12I in p2 and T24I in NC (Liang et al., 1998).
This difference suggests that even though both SL1 and SL3
participate in RNA packaging via binding to Gag (Clever et
al., 1995), the detailed RNA-protein interactions may vary.
In support of this notion, the A11V and I12V mutations
could not rescue the SL1-deleted viruses in regard to its
crippled viability as well as defective RNA packaging and
dimerization (data not shown).
Compensation of the deleted SL1 and SL3 sequences by
their relevant suppressor mutations involves restoration of
wild-type RNA packaging. Yet, in contrast to mutations
A11V and I12V that also corrected the defective dimeriza-
tion caused by the deleted SL3 sequences, mutations T12I
and T24I could not fix the defective dimers associated with
the deleted SL1 sequences (Shen et al., 2000). Thus, SL1
and SL3 may regulate viral RNA dimerization via distinct
mechanisms. Results of cell-free assays show that SL1 is
able to form dimers spontaneously without the assistance of
any viral or cellular proteins by virtue of its palindrome loop
sequence (Clever et al., 1996; Laughrea and Jette, 1994,
1996; Marquet et al., 1994; Mujeeb et al., 1998; Muriaux et
al., 1995, 1996b; Paillart et al., 1994, 1996; Skripkin et al.,
1994); in contrast, short synthetic viral RNA fragments
containing the SL3 sequence do not dimerize (Sundquist
and Heaphy, 1993). Antisense DNA oligonucleotides, tar-
geting either SL1 or SL3, were able to block dimerization of
synthetic viral RNA fragments. However, the SL3-antisense
molecules bound to RNA dimers while the SL1-antisense
molecules did not, perhaps because SL1 already forms
“Watson-Crick” basepairs within dimers and SL3 may have
been involved in other types of molecular interactions
(Zhang et al., 1997).
Rescue of the deleted SL3 sequences by second-site
mutations in p2 (A11V) and NC (I12V) involves increases
in the levels of both RNA packaging and dimerization. It is
thus possible that increased dimerization is a result of op-
timized RNA packaging. Although we cannot rule out this
possibility at this stage, studies performed with PR-negative
viruses indicate that the A11V and I12V mutations cannot
rescue defective immature dimers caused by the (306–
325) deletion (Fig. 5). Together with the fact that these two
substitutions can increase packaging of (306–325) RNA
to wild-type levels (Fig. 3), we conclude that to the least
extent, the early defects in dimerization caused by (306–
325) prior to PR cleavage are irrelevant to the deficient
packaging of (306–325) RNA.
Since SL1 and SL3 are closely located within viral RNA
genome, it is possible that deletion of SL3 may have inter-
fered with the folding of the SL1 structure, and thereby
indirectly affected dimerization. This seems unlikely, since
the results of RNA secondary structure prediction by the
M-Fold program show that deletion of SL3 still allows the
correct folding of SL1 as well as the other structures within
the noncoding RNA leader region (Fig. 1B). Therefore,
although results of computer modeling need to be further
verified by structural probing experiments, it is highly pos-
sible that the (306–325) deletion may have disturbed RNA
dimerization through mechanisms other than disruption of
the SL1 structure.
We hypothesize that the involvement of SL3 in RNA
dimerization may be related to its NC-binding activity
(Berkowitz et al., 1993, 1994; Clever et al., 1995; Sakaguchi
et al., 1993). NC has been shown to promote dimerization of
synthetic viral RNA fragments (Feng et al., 1996; Muriaux
et al., 1996a), and mutations within NC zinc finger motifs
led to deficient viral RNA dimerization within virions
(Laughrea et al., 2001). Therefore, the role of SL3 in dimer-
ization may partially be due to its function in the specific
recruitment of NC onto viral RNA.
Notably, compensation of mutated RNA packaging sig-
nals (e.g., SL1 or SL3) involves second-site mutations in the
p2 sequence (e.g., T12I and A11V); this indicates a poten-
tial role of p2 in recognition of viral RNA during viral
assembly. Indeed, presence of HIV-1 p2 sequence, together
with NC, in an HIV-1/HIV-2 chimeric virus significantly
augments specific packaging of HIV-1 RNA; this consti-
tutes the first evidence that p2 may play important roles in
HIV-1 RNA packaging (Kaye and Lever, 1998).
Together with our previous findings obtained with the
deleted SL1 sequences (Liang et al., 1998), this study fur-
ther demonstrates that HIV-1 is capable of surviving par-
tially removed RNA packaging signals by modifying the
Gag sequences. Presumably, these modified Gag proteins
Fig. 5. Effects of the (306–325) deletion on RNA dimerization in the
PR virus. Construct (306–325)-R-PR contains the (306–325) dele-
tion, the second-site mutations A11V and I12V, as well as PR mutation
D25A.
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must have possessed wild-type levels of binding affinity for
the mutated viral RNA and thus restored wild-type RNA
packaging.
Materials and methods
Plasmid construction
The BH10 infectious HIV-1 cDNA clone was employed
as starting material. Mutagenesis studies were performed on
the basis of polymerase chain reactions (PCR) using Pfu
enzyme with 3 to 5 proof-reading activity (Stratagene, La
Jolla, CA). The primers used were purchased from Invitro-
gen (Burlington, Ontario, Canada). The (306–325) dele-
tion was engineered through use of primer pairs
pSL3(5-CTGAAGCGCGCACGGCAAGAGGCGAGGG-
GCGGCGACTGGTGAGTACGCCAAAAAAAGGAGAG-
AGATGGG-3, [nt 252 to 340])/pAPA-A(5-CCTAGG-
GGCCCTGCAATTTCTG-3 [nt 1562 to 1541]). The PCR
products were digested with restriction enzymes BssHII and
ApaI (Invitrogen) and used to replace the same regions in
BH10.
The A11V amino acid substitution in p2 was created by
using a PCR-Script Amp cloning kit (Stratagene) through
use of primers p2-S2 (5-GTAACAAATTCAGTTAC-
CATAATGATGCAG-3 [nt 1443 to 1472])/p2-A2 (5-
GCATCATTATGGTAACTGAATTTGTTACTTGG-3 [nt
1470 to 1439]). The I12V mutation in the NC sequence was
engineered by PCR by using primer pair pE (5-GGAAC-
CAAAGAAAGGTTGTTAAGTGTTTC-3 [nt 1486 to
1514])/pNC-A (5-TTAGCCTGTCTCTCAGTACAATC-3
[nt 1630 to 1608]). The PCR product was used as a primer
in a second round of PCR together with primer pSph-S
(5-AGTGCATCCAGTGCATGCAGGGCC-3 [nt 977 to
1000]). The final PCR product was digested with SphI and
ApaI and inserted into (306–325). The positions of prim-
ers are in relation to the first nt of the 5 R region. The
mutations generated were confirmed by sequencing.
Cell culture, transfection, and infection
COS-7 and MT-2 cells were grown in Dulbecco’s mod-
ified Eagle’s medium (DMEM) and RPMI 1640 medium,
respectively, supplemented with 10% fetal calf serum (In-
vitrogen). Transfection of COS-7 cells was performed with
Lipofectamine (Invitrogen). Progeny virus in culture fluids
were collected 48 h after transfection and quantified by
measuring levels of HIV-1 CA (p24) antigen (Ag) by en-
zyme-linked immunosorption assays (ELISA) (Vironostika
HIV-1 Antigen Microelisa System, Organon Teknika Cor-
poration, Durham, NC).
Viruses containing 3 ng of p24 were used to infect 5 
105 MT-2 cells in 2 ml of RPMI 1640 medium. After 2 h,
cells were washed twice to remove unbound viruses and
were grown in 10 ml of complete medium. Growth of
viruses was monitored by measuring reverse transcriptase
(RT) activity of culture fluids at various times.
Analysis of viral proteins
COS-7 cells were transfected for 20 h, followed by
starvation in DMEM without Met and Cys at 37°C for 2 h.
Total cellular proteins were then radiolabeled by 35S-Met
and 35S-Cys (ICN, Irvine, CA) at a concentration of 0.1
mCi/ml for 30 min at 37°C. The labeled cells were either
lysed immediately after labeling or cultured for an addi-
tional hour in complete DMEM before being lysed in NP-40
lysis buffer. Cell lysates were incubated with monoclonal
antibodies (mAbs) against HIV-1 p24 and the Ag:mAb
complexes were absorbed with protein A-linked Sepharose
4B (Amersham Pharmacia Biotech., Baie d’Urfe, Quebec,
Canada). After extensive washing, the immunoprecipitated
viral proteins were fractionated on sodium dodecyl sulfate
(SDS)-12% polyacrylamide gels and visualized by exposure
to x-ray films (Kodak, Rochester, NY). The 35S-labeled
virus particles in the culture fluids were collected through
centrifugation and directly analyzed by running on SDS-
12% polyacrylamide gels.
Analysis of viral RNA by Northern blots
Progeny viruses generated by transfected COS-7 cells
were first clarified by centrifugation in a Beckman GR-6S
centrifuge at 3000 rpm for 30 min at 4°C and then pelleted
through a 20% sucrose cushion by ultracentrifugation in a
Beckman XL-80 ultracentrifuge using an SW41 rotor at
40,000 rpm for 1 h at 4°C. Virus pellets were suspended in
300 l of TN buffer, a 2-l portion was removed for p24
determination, and the remaining viruses were digested with
100 g/ml protease K in the presence of 1% SDS, 10 mM
EDTA, 100 mM NaCl, and 50 g of yeast tRNA for 20 min
at 37°C. Samples were then extracted twice with phenol:
chlorophorm:isoamlyalcohol (25:24:1) and once with chlo-
roform. Viral RNA was precipitated in 2.5 volumes of 95%
ethanol. RNA pellets were washed with 70% ethanol and
dissolved in TE buffer. An amount of viral RNA equivalent
to 150 ng of HIV-1 p24 was electrophoresed on 0.9% native
agarose gels in 1  TBE buffer at 100 V for 4 h at 4°C. The
RNA was then transferred to a nylon membrane and ana-
lyzed by Northern blots using 32P--dCTP (ICN) labeled
HIV-1 DNA probes. To determine the thermostability of
viral RNA dimers, RNA samples were treated at various
temperatures (e.g., 40°C, 45°C, 50°C, and 55°C) for 10 min
in a buffer containing 100 mM NaCl before being separated
on native agarose gels.
To assess the expression of both full-length and spliced
forms of viral RNA, total RNA was extracted from trans-
fected COS-7 cells and separated on 1% agarose gels con-
taining formaldehyde as a denaturant. RNA molecules were
then transferred onto a nylon membrane and hybridized to
HIV-1 probes as described above.
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Identification of second-site mutations
MT-2 cells that had been infected with mutated viruses
were cultured for prolonged periods until formation of syn-
cytia and high levels of RT activity were observed. The
infectious virus particles were further used to infect fresh
MT-2 cells until wild-type replication kinetics were seen.
Cellular DNA was then extracted from infected MT-2 cells
and subjected to PCR and sequencing to identify newly
emerged second-site mutations in proviral DNA (Liang et
al., 1998).
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